Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1CNS 1

Conditions

beta-Thalassemia 1Seizures 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Seizures After Brain Tumor Surgery 1Neurofibromatosis 1 1Neuroblastoma 1Neoplasm, Residual 1Necrosis 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Influenza, Human 1Hematologic Neoplasms 1Chromosome Aberrations 1Chromosome 7, monosomy 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

thymoglobulin 2fludarabine 2Rituximab 2Cyclophosphamide 2luspatercept 1Tacrolimus 1Mycophenolic Acid 1Melphalan 1Levetiracetam 1Dexamethasone 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Levetiracetam × 90 days × Clear all
NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
70 enrolled
CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡